NCT02063230 - To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Solid Tumors

Interventions

DRUG

Selumetinib 50mg

HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1

DRUG

Selumetinib 25mg

Severe (Child Pugh C) hepatic impaired patients will receive selumetinib 25mg orally on Day 1

Trial Locations (1)

Research Site, Orlando